Skip to main content
. 2021 Feb 13;10(10):1242–1247. doi: 10.1002/cpdd.920

Figure 2.

Figure 2

Baseline (before breakfast and first dose of the day) and postprandial (highest concentration after lunch and second dose) individual (left) and mean ± standard deviation (right) orlistat plasma concentrations at day 14 for test product modified‐release oral capsule with orlistat and acarbose (MR‐OA; “EMP16 120/40”) and reference product with orlistat 120 mg (“Conventional orlistat”).